A5080505420- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Chemotherapy-related skin toxicity
- Bone health and treatments
- Cancer Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Radiopharmaceutical Chemistry and Applications
- Management of metastatic bone disease
- Cancer survivorship and care
- Advanced Breast Cancer Therapies
- Health Systems, Economic Evaluations, Quality of Life
- Palliative Care and End-of-Life Issues
- Economic and Financial Impacts of Cancer
- Oral health in cancer treatment
- Multiple Myeloma Research and Treatments
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Cancer-related cognitive impairment studies
- Glioma Diagnosis and Treatment
- Global Maternal and Child Health
- Blood disorders and treatments
- Colorectal Cancer Treatments and Studies
- HIV/AIDS Research and Interventions
- Cardiac Valve Diseases and Treatments
- Prostate Cancer Treatment and Research
NOSM University
2020-2024
Abdul Wali Khan University Mardan
2024
Cairo University
2024
Universitätsklinikum Erlangen
2023
Thunder Bay Regional Health Sciences Centre
2021-2022
Ottawa Hospital
2014-2021
University of Ottawa
2014-2021
Jimma University
2021
Lakehead University
2021
Michigan Healthcare Professionals
2019-2020
Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic urothelial carcinoma. In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy improves overall survival. Tumor PD-L1 expression increases in MIBC after NAC, suggesting potential synergy combining PD1/PD-L1 NAC. IDO1 is overexpressed and associated poor outcomes. Linrodostat mesylate (BMS-986205) – a selective, potent, oral...
•Multicentre randomised trial of 466 breast cancer patients compared schedules filgrastim administration.•Provides real-world data showing use beyond 5 days did not significantly improve co-primary or secondary outcomes.•5 should be considered the standard care. BackgroundThe optimal duration as primary febrile neutropenia (FN) prophylaxis in early is unknown, with 5, 7 10 being commonly prescribed. This evaluates whether was non-inferior to 7/10 days.Patients and methodsIn this randomised,...
Objective: To measure changes in service utilization of a model integrating family planning with HIV counselling and testing (HCT), antiretroviral therapy (ART) prevention mother-to-child transmission (PMTCT) the Nigerian public health facilities. Design: It is retrospective survey attendance commodity uptake 71 facilities Nigeria that analyzes preintegration postintegration periods between March 2007 January 2009. Methods: A prepost comparison mean at clinics couple-years protection (CYP)...
Abstract Background: Granulocyte colony stimulating factor (G-CSF) such as filgrastim (FIL) or pegfilgrastim (PEG) significantly reduces the risk of febrile neutropenia (FN) and treatment-related hospitalization in patients with early breast cancer receiving chemotherapy. However, G-CSF can experience clinically significant bone pain. Previous studies examining post-GCSF pain were mostly based on physician assessment compared mixed doses (30/60/100 μg/kg) PEG vs. FIL (5μg/kg/day 300 μg/day)...
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free publicly available algorithms (e.g., PREDICT 2.1) expensive molecular assays Oncotype DX). There remains a need identify patients who de-rive the most from where this test may be of poor value. In multicenter prospective cohort study, we evaluated whether use 2.1 would impact physician decision making. first 6 months data on both DX ordering were collected all...
Despite advances in therapy, bone remains the most common site of prostate cancer recurrence [...]
<i>Background:</i> Computer users are at high risk to experience eye discomfort and vision problems when viewing digital screens for extended periods. These collectively termed Vision Syndrome (CVS). Nearly more than 60 million people suffer from CVS globally with a new cases occurring each year. The magnitude of its determinants not well known in Ethiopia. Thus, the aim study was determine prevalence predictors among secretary employees working Jimma University, <i>Methods:</i> An...
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended docetaxel-cyclophosphamide (TC) chemotherapy for early-stage breast cancer (EBC). A pragmatic randomised trial compared the superiority of G-CSF to and a cost-utility analysis were conducted.